The Experts below are selected from a list of 22692 Experts worldwide ranked by ideXlab platform
Joseph H. Coggin - One of the best experts on this subject based on the ideXlab platform.
-
37 kilodalton oncofetal Antigen protein and immature laminin receptor protein are identical universal t cell inducing immunogens on primary rodent and human cancers
Anticancer Research, 1999Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:, Based upon positive immunogologic comparisons, protein and cDNA sequencing, and in vitro and in vivo immunogenicity studies we propose that carcinomas, sarcomas and lymphomas/leukemias of rodents and humans share 37kDa Onco-Fetal Antigen [OFA] as a T and B-lymphocyte stimulating, universal tumor specific Transplantation Antigen lating, universal tumor specific Transplantation Antigen [UTSTA]. In the past four years, biochemical studies from several laboratories studying laminin receptor protein and immunological studies of OFA from our laboratories independently converged. OFA protein and immature or precursor Laminin Receptor Protein [iLRP] are >99% identical proteins based on amino acid and cDNA sequencing and immunobiology studies summarized here. Acquired expression of immunobiology studies summarized here. Acquired expression of 37kDa OFA/iLRP enables malignant tumor cells to penetrate laminin tissue and vessel barriers. 37kDa OFA/iLRP activates precursor thymic anti-OFA/iLRP specific cytotoxic T cell which kill emerging pretumor cells. Our reported findings also demonstrate that OFA/iLRP can function to induce specific immunoregulatory CD8 T-suppressor cells secreting IL-10 which impair effector T-cell killing of emerging tumor cells non-specifically and thereby facilitate tumor progression. Potential applications of OFA/iLRP detection in early cancer formation, for monitoring patient T cell subclass responses to OFA/iLRP as a predictor of tumor progression, and the use of OFA/iLRP peptides for specific anti-tumor immunotherapy are presented.
-
Tumors express both unique TSTA and crossprotective 44 kDa oncofetal Antigen
Immunology today, 1998Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:Abstract Tumors of inbred rodents and humans generally express a shared tumor-associated Transplantation Antigen (TATA)-like oncofetal Antigen (OFA) and tumor-specific Transplantation Antigen (TSTA), which stimulate cytotoxic T lymphocyte (CTL) tumor rejection responses. Immunoregulatory CD8 + OFA-specific suppressor T cells are also stimulated, which promote tumor development via interleukin 10 secretion, inhibiting CTL function. Here, Joseph Coggin and colleagues argue that future investigations must distinguish responses to OFA and TSTA.
-
differential recognition of murine tumor associated oncofetal Transplantation Antigen and individually specific tumor Transplantation Antigens by syngeneic cloned balb c and rfm mouse t cells
Journal of Immunology, 1994Co-Authors: James W. Rohrer, Adel L. Barsoum, S. D. Rohrer, Joseph H. CogginAbstract:We have previously demonstrated in several species that sarcomas, lymphomas, and carcinomas express a common Ag that cross-reacts with midgestation fetal cells. We also produced a mAb to that protein and characterized it as a 44-kDa glycoprotein. The cross-reactive immunity induced by immunization with tumor or fetal cells expressing the oncofetal Ag (OFA) can be adoptively transferred with cell populations containing T lymphocytes. The experiments discussed within this paper describe the establishment and characterization of two types of T lymphocytes induced by immunization with syngeneic tumor cells in two mouse strains. We find that five of the eight cloned T cells derived from spleens of BALB/c mice that had been immunized with MCA1315 fibrosarcoma cells are specific for an Ag shared by MCA1315 and MCA1321 cells. The other three clones are specific for an Ag present on MCA1315 but not on MCA1321. Also, none of the clones were reactive with the BALB/c plasmacytoma MOPC-315, which does not express OFA. We also find that 75% of the RFM T cell clones from spleens of RFM mice immune to the RFM thymoma 5T show a 5T-specific proliferative response. One of the four clones, however, responds to both 4T and 5T RFM thymoma cells. The BALB/c and RFM cross-reactive clones specifically respond to purified 44-kDa OFA derived from MCA1315 fibrosarcoma cells in the presence of syngeneic irradiated spleen cells and IL-2. All of the clones from both strains of mice, be they tumor-specific Transplantation Ag specific or OFA specific, are CD4+, CD3+, alpha beta TCR+ T cells that secrete IFN-gamma on Ag stimulation.
-
44-kd Oncofetal Transplantation Antigen in Rodent and Human Fetal Cells: Implications of Recrudescence in Human and Rodent Cancers
Archives of otolaryngology--head & neck surgery, 1993Co-Authors: Joseph H. Coggin, Adel L. Barsoum, Shirley D. Rohrer, Raymond D. Hester, Haroon-ur Rashid, Gerald S. GussackAbstract:Objective: This article summarizes the phase-specific nature of a cell surface, 44-kd tumor-associated Transplantation Antigen glycoprotein expressed during early and middle gestation in a portion of rodent and human fetal cells during normal fetal tissue development and illustrates how this glycoprotein is consistently recrudesced in primary and established human squamous cell carcinomas and other human and rodent tumors. The oncofetal Antigen was not detectable in any human or rodent term fetal tissue or normal adult tissues tested. The tumor-associated Transplantation Antigen was tumor specific, yet not germ-line specific (expressed in lymphomas, sarcomas, and carcinomas) in human or rodent cancers. Rodent model tumor studies have shown 44-kd oncofetal Antigen can act as a tumor-associated autoAntigen of potential use in cancer detection and therapy. Design: The oncofetal Antigen was detected by immunogenicity, flow cytometry, and Western blotting in syngeneic rodent tumor recipients and by the last two methods in humans with progressive cancer. Syngeneically derived mouse monoclonal antibody (MoAb 115) was used to identify 44-kd oncofetal Antigen. Early to middle gestation, oncofetal Antigen—positive, mouse embryo/fetal cells used to stimulate the hybridoma were tested for immunogenicity as a tumor-associated Transplantation Antigen in syngeneic hosts. Setting and Patients: Patients presenting with head and neck squamous cell carcinoma (N=25) and other carcinomas at the University of South Alabama Medical Center, Mobile, underwent a biopsy, and the tumors were mechanically dispersed and were then tested for oncofetal Antigen expression directly in flow cytometry. The tumors were also cultured and tested as squamous carcinoma cell lines. Growing squamous carcinoma cells and uncultured tumor cells were stained with MoAb 115 or control MoAb. Extracts of the cells were banded by electrophoresis in gels, Western blotted, and reacted with MoAbs and enzyme-linked immunosorbent assay second antibody. Time-mated mouse fetus and human fetal cells were also stained with MoAb 115 or control antibody and analyzed in the flow cytometer. Results: Eight- to 13-day mouse fetal cells conferred protection against syngeneic tumor challenge. Term 18- to 21-day fetal or neonate or adult mouse cells were nonprotective. All head and neck squamous cell carcinomas tested expressed 44-kd oncofetal Antigen by flow cytometric analysis and in Western blots as did ATCC cell lines of these tumors, whereas normal control tissues were negative. Second trimester human fetal cells were 44-kd oncofetal Antigen positive. A large spectrum of rodent sarcomas and lymphomas express the OFA. Conclusions: Shared 44-kd oncofetal Antigen OFA offers promise as a tumor detection marker in human squamous cell carcinoma and other human carcinoma development, and syngeneic mouse tumors are good model systems to explore oncofetal Antigen Antigenicity. (Arch Otolaryngol Head Neck Surg. 1993;119:1257-1266)
Adel L. Barsoum - One of the best experts on this subject based on the ideXlab platform.
-
37 kilodalton oncofetal Antigen protein and immature laminin receptor protein are identical universal t cell inducing immunogens on primary rodent and human cancers
Anticancer Research, 1999Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:, Based upon positive immunogologic comparisons, protein and cDNA sequencing, and in vitro and in vivo immunogenicity studies we propose that carcinomas, sarcomas and lymphomas/leukemias of rodents and humans share 37kDa Onco-Fetal Antigen [OFA] as a T and B-lymphocyte stimulating, universal tumor specific Transplantation Antigen lating, universal tumor specific Transplantation Antigen [UTSTA]. In the past four years, biochemical studies from several laboratories studying laminin receptor protein and immunological studies of OFA from our laboratories independently converged. OFA protein and immature or precursor Laminin Receptor Protein [iLRP] are >99% identical proteins based on amino acid and cDNA sequencing and immunobiology studies summarized here. Acquired expression of immunobiology studies summarized here. Acquired expression of 37kDa OFA/iLRP enables malignant tumor cells to penetrate laminin tissue and vessel barriers. 37kDa OFA/iLRP activates precursor thymic anti-OFA/iLRP specific cytotoxic T cell which kill emerging pretumor cells. Our reported findings also demonstrate that OFA/iLRP can function to induce specific immunoregulatory CD8 T-suppressor cells secreting IL-10 which impair effector T-cell killing of emerging tumor cells non-specifically and thereby facilitate tumor progression. Potential applications of OFA/iLRP detection in early cancer formation, for monitoring patient T cell subclass responses to OFA/iLRP as a predictor of tumor progression, and the use of OFA/iLRP peptides for specific anti-tumor immunotherapy are presented.
-
Tumors express both unique TSTA and crossprotective 44 kDa oncofetal Antigen
Immunology today, 1998Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:Abstract Tumors of inbred rodents and humans generally express a shared tumor-associated Transplantation Antigen (TATA)-like oncofetal Antigen (OFA) and tumor-specific Transplantation Antigen (TSTA), which stimulate cytotoxic T lymphocyte (CTL) tumor rejection responses. Immunoregulatory CD8 + OFA-specific suppressor T cells are also stimulated, which promote tumor development via interleukin 10 secretion, inhibiting CTL function. Here, Joseph Coggin and colleagues argue that future investigations must distinguish responses to OFA and TSTA.
-
differential recognition of murine tumor associated oncofetal Transplantation Antigen and individually specific tumor Transplantation Antigens by syngeneic cloned balb c and rfm mouse t cells
Journal of Immunology, 1994Co-Authors: James W. Rohrer, Adel L. Barsoum, S. D. Rohrer, Joseph H. CogginAbstract:We have previously demonstrated in several species that sarcomas, lymphomas, and carcinomas express a common Ag that cross-reacts with midgestation fetal cells. We also produced a mAb to that protein and characterized it as a 44-kDa glycoprotein. The cross-reactive immunity induced by immunization with tumor or fetal cells expressing the oncofetal Ag (OFA) can be adoptively transferred with cell populations containing T lymphocytes. The experiments discussed within this paper describe the establishment and characterization of two types of T lymphocytes induced by immunization with syngeneic tumor cells in two mouse strains. We find that five of the eight cloned T cells derived from spleens of BALB/c mice that had been immunized with MCA1315 fibrosarcoma cells are specific for an Ag shared by MCA1315 and MCA1321 cells. The other three clones are specific for an Ag present on MCA1315 but not on MCA1321. Also, none of the clones were reactive with the BALB/c plasmacytoma MOPC-315, which does not express OFA. We also find that 75% of the RFM T cell clones from spleens of RFM mice immune to the RFM thymoma 5T show a 5T-specific proliferative response. One of the four clones, however, responds to both 4T and 5T RFM thymoma cells. The BALB/c and RFM cross-reactive clones specifically respond to purified 44-kDa OFA derived from MCA1315 fibrosarcoma cells in the presence of syngeneic irradiated spleen cells and IL-2. All of the clones from both strains of mice, be they tumor-specific Transplantation Ag specific or OFA specific, are CD4+, CD3+, alpha beta TCR+ T cells that secrete IFN-gamma on Ag stimulation.
-
44-kd Oncofetal Transplantation Antigen in Rodent and Human Fetal Cells: Implications of Recrudescence in Human and Rodent Cancers
Archives of otolaryngology--head & neck surgery, 1993Co-Authors: Joseph H. Coggin, Adel L. Barsoum, Shirley D. Rohrer, Raymond D. Hester, Haroon-ur Rashid, Gerald S. GussackAbstract:Objective: This article summarizes the phase-specific nature of a cell surface, 44-kd tumor-associated Transplantation Antigen glycoprotein expressed during early and middle gestation in a portion of rodent and human fetal cells during normal fetal tissue development and illustrates how this glycoprotein is consistently recrudesced in primary and established human squamous cell carcinomas and other human and rodent tumors. The oncofetal Antigen was not detectable in any human or rodent term fetal tissue or normal adult tissues tested. The tumor-associated Transplantation Antigen was tumor specific, yet not germ-line specific (expressed in lymphomas, sarcomas, and carcinomas) in human or rodent cancers. Rodent model tumor studies have shown 44-kd oncofetal Antigen can act as a tumor-associated autoAntigen of potential use in cancer detection and therapy. Design: The oncofetal Antigen was detected by immunogenicity, flow cytometry, and Western blotting in syngeneic rodent tumor recipients and by the last two methods in humans with progressive cancer. Syngeneically derived mouse monoclonal antibody (MoAb 115) was used to identify 44-kd oncofetal Antigen. Early to middle gestation, oncofetal Antigen—positive, mouse embryo/fetal cells used to stimulate the hybridoma were tested for immunogenicity as a tumor-associated Transplantation Antigen in syngeneic hosts. Setting and Patients: Patients presenting with head and neck squamous cell carcinoma (N=25) and other carcinomas at the University of South Alabama Medical Center, Mobile, underwent a biopsy, and the tumors were mechanically dispersed and were then tested for oncofetal Antigen expression directly in flow cytometry. The tumors were also cultured and tested as squamous carcinoma cell lines. Growing squamous carcinoma cells and uncultured tumor cells were stained with MoAb 115 or control MoAb. Extracts of the cells were banded by electrophoresis in gels, Western blotted, and reacted with MoAbs and enzyme-linked immunosorbent assay second antibody. Time-mated mouse fetus and human fetal cells were also stained with MoAb 115 or control antibody and analyzed in the flow cytometer. Results: Eight- to 13-day mouse fetal cells conferred protection against syngeneic tumor challenge. Term 18- to 21-day fetal or neonate or adult mouse cells were nonprotective. All head and neck squamous cell carcinomas tested expressed 44-kd oncofetal Antigen by flow cytometric analysis and in Western blots as did ATCC cell lines of these tumors, whereas normal control tissues were negative. Second trimester human fetal cells were 44-kd oncofetal Antigen positive. A large spectrum of rodent sarcomas and lymphomas express the OFA. Conclusions: Shared 44-kd oncofetal Antigen OFA offers promise as a tumor detection marker in human squamous cell carcinoma and other human carcinoma development, and syngeneic mouse tumors are good model systems to explore oncofetal Antigen Antigenicity. (Arch Otolaryngol Head Neck Surg. 1993;119:1257-1266)
James W. Rohrer - One of the best experts on this subject based on the ideXlab platform.
-
37 kilodalton oncofetal Antigen protein and immature laminin receptor protein are identical universal t cell inducing immunogens on primary rodent and human cancers
Anticancer Research, 1999Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:, Based upon positive immunogologic comparisons, protein and cDNA sequencing, and in vitro and in vivo immunogenicity studies we propose that carcinomas, sarcomas and lymphomas/leukemias of rodents and humans share 37kDa Onco-Fetal Antigen [OFA] as a T and B-lymphocyte stimulating, universal tumor specific Transplantation Antigen lating, universal tumor specific Transplantation Antigen [UTSTA]. In the past four years, biochemical studies from several laboratories studying laminin receptor protein and immunological studies of OFA from our laboratories independently converged. OFA protein and immature or precursor Laminin Receptor Protein [iLRP] are >99% identical proteins based on amino acid and cDNA sequencing and immunobiology studies summarized here. Acquired expression of immunobiology studies summarized here. Acquired expression of 37kDa OFA/iLRP enables malignant tumor cells to penetrate laminin tissue and vessel barriers. 37kDa OFA/iLRP activates precursor thymic anti-OFA/iLRP specific cytotoxic T cell which kill emerging pretumor cells. Our reported findings also demonstrate that OFA/iLRP can function to induce specific immunoregulatory CD8 T-suppressor cells secreting IL-10 which impair effector T-cell killing of emerging tumor cells non-specifically and thereby facilitate tumor progression. Potential applications of OFA/iLRP detection in early cancer formation, for monitoring patient T cell subclass responses to OFA/iLRP as a predictor of tumor progression, and the use of OFA/iLRP peptides for specific anti-tumor immunotherapy are presented.
-
Tumors express both unique TSTA and crossprotective 44 kDa oncofetal Antigen
Immunology today, 1998Co-Authors: Joseph H. Coggin, Adel L. Barsoum, James W. RohrerAbstract:Abstract Tumors of inbred rodents and humans generally express a shared tumor-associated Transplantation Antigen (TATA)-like oncofetal Antigen (OFA) and tumor-specific Transplantation Antigen (TSTA), which stimulate cytotoxic T lymphocyte (CTL) tumor rejection responses. Immunoregulatory CD8 + OFA-specific suppressor T cells are also stimulated, which promote tumor development via interleukin 10 secretion, inhibiting CTL function. Here, Joseph Coggin and colleagues argue that future investigations must distinguish responses to OFA and TSTA.
-
differential recognition of murine tumor associated oncofetal Transplantation Antigen and individually specific tumor Transplantation Antigens by syngeneic cloned balb c and rfm mouse t cells
Journal of Immunology, 1994Co-Authors: James W. Rohrer, Adel L. Barsoum, S. D. Rohrer, Joseph H. CogginAbstract:We have previously demonstrated in several species that sarcomas, lymphomas, and carcinomas express a common Ag that cross-reacts with midgestation fetal cells. We also produced a mAb to that protein and characterized it as a 44-kDa glycoprotein. The cross-reactive immunity induced by immunization with tumor or fetal cells expressing the oncofetal Ag (OFA) can be adoptively transferred with cell populations containing T lymphocytes. The experiments discussed within this paper describe the establishment and characterization of two types of T lymphocytes induced by immunization with syngeneic tumor cells in two mouse strains. We find that five of the eight cloned T cells derived from spleens of BALB/c mice that had been immunized with MCA1315 fibrosarcoma cells are specific for an Ag shared by MCA1315 and MCA1321 cells. The other three clones are specific for an Ag present on MCA1315 but not on MCA1321. Also, none of the clones were reactive with the BALB/c plasmacytoma MOPC-315, which does not express OFA. We also find that 75% of the RFM T cell clones from spleens of RFM mice immune to the RFM thymoma 5T show a 5T-specific proliferative response. One of the four clones, however, responds to both 4T and 5T RFM thymoma cells. The BALB/c and RFM cross-reactive clones specifically respond to purified 44-kDa OFA derived from MCA1315 fibrosarcoma cells in the presence of syngeneic irradiated spleen cells and IL-2. All of the clones from both strains of mice, be they tumor-specific Transplantation Ag specific or OFA specific, are CD4+, CD3+, alpha beta TCR+ T cells that secrete IFN-gamma on Ag stimulation.
John S. Najarian - One of the best experts on this subject based on the ideXlab platform.
-
Variables in an Assay of Soluble Human Transplantation Antigens
Tissue antigens, 2008Co-Authors: Edward E. Etheredge, Barbara H. Franecki, John S. NajarianAbstract:The data demonstrate that an assay for soluble human Transplantation Antigen, based on the inhibition of a two-stage lymphocytotoxicity reaction, is (A) affected by platelet contamination of the target lymphocyte suspension; (B) more sensitive to low Antigen concentration if antisera are diluted to titer using AB serum; (C) responsive to the particular antiserum-target cell combination used; (D) relatively insensitive to the solvent of the protein solution; (E) markedly affected by the concentration of the protein solution being tested; (F) maximally sensitive to low Antigen concentration with the following conditions: (1) a one-hour incubation of Antigen and antiserum at room temperature, (2) a 40-minute incubation at room temperature for the interaction of the Antigen-antiserum and cells, and (3) incubation with complement for 20 minutes at 37° C; (G) more sensitive to rabbit complement than an equal mixture of rabbit and human complement, for the sera studied.
Ronald B. Herberman - One of the best experts on this subject based on the ideXlab platform.
-
Serologic Analysis of the Antigenic Specificities of Simian Virus 40-Transformed Cells and Their Relationship to Tumor-Associated Transplantation Antigen 1,2
2016Co-Authors: Chou-chik Ling, John R. Ortaldo, Ronald B. HerbermanAbstract:SUMMARY-In tests with the isotopic antiglobulin tech-nique, the antisera produced by immunization of (BALB/c X C57BL)F1 mice with syngeneic simian virus 40 (SV40) tumor (SVT2) reacted against at least 2 different specifici-ties. Some sera only reacted with the tumor-associated cell-surface Antigen (TASA) of SV40-transformed cells. Other sera also reacted with a common Antigen found in non-SV40 tumor cells but not in normal spleen cells. Only TASA was found to be correlated with the tumor-associated Transplantation Antigen. Although all sera reacted with various SV40-transformed cells, they had different pat-terns of reactivity. These results indicate that the SV40 TASA may be composed either of different molecules or of single molecules with several Antigenic determinants.-J Natl Cancer Inst 52: 815-821,1974. SIMIAN VIRUS 40 (SV40)-transformed cells possess an Antigen specific for SV40-induced tumors and absent in non-SV40-induced tumors, which has been demonstrated both in in vivo and in vitro (1-6). Recently, common Antigens in hamster SV40 tumors were found to be shared by both SV40 tumors and non-SV40 cells, e.g., Forssman Antigen (7), organ-specific Antigens (8), Antigen uncovered by trypsin treatment (9), and fetal Antigen (10, 11). Immuniza-tion with fetal tissue was also reported to weakly protect hamsters against SV40 tumor (12). The present study shows that immunizing with SV40 tumor cells elicits antibodies reacting against both the SV40 tumor-associated cell-surface Antigen (TASA) and also against common Antigen(s). We also investigate the relationship of these Antigens to SV40 tumor-associated Transplantation Antigen (TA
